**Preclinical Activity and Safety of STRO-002, a Novel ADC Targeting Folate Receptor Alpha for Ovarian Cancer**

**Cristina Abraham,** **Stefanie Kim**, **Xiaofan Li,** **Zhihong Zhou,** **Jeffery Hanson,** **Mary Rose Masaki,** **Krisha Bajuri,** **Tyler Heiberg,** **Debbie Kohari,** **Abigail Yu,** **Robert Henranga,** **Cuan Tran**

*Abstract*

STRO-002 is a novel antibody-drug conjugate (ADC) that targets the folate receptor alpha (FolRα) on ovarian cancer cells. This study evaluated the in vivo activity and safety of STRO-002.

**Materials and Methods**

STRO-002 was evaluated in a xenograft model of ovarian cancer (Igrov-1 and OVSAHO cells) and in cell-based assays. The in vivo activity of STRO-002 was assessed in mice bearing Igrov-1 tumors, and its safety was evaluated in monkeys.

**Results**

**Preclinical Activity**

- STRO-002 demonstrated significant anti-tumor activity in Igrov-1 and OVSAHO cells, with an ~10-fold increase in tumor size on day 21 for the vehicle control group compared to the same endpoint. Statistical analysis was performed using two-way ANOVA with Dunnett’s multiple comparisons test.

- In vivo, 8.7 mg/kg STRO-002 was tolerated at 0.9, 2.9, and 8.7 mg/kg following two IV treatments in monkeys.

**Safety Parameters**

- No significant differences were observed in relative cell viability assays between the drug vehicle and STRO-002.

- The relative cell viability of cell lines treated with STRO-002 was compared to the vehicle control group.

- The relative cell viability of cell lines treated with STRO-002 was compared to the vehicle control group.

- The relative cell viability of cell lines treated with STRO-002 was compared to the vehicle control group.

- The relative cell viability of cell lines treated with STRO-002 was compared to the vehicle control group.

**Discussion**

These findings are consistent with the antigen-independent activity of STRO-002, which is not limited to FolRα expression.

**Acknowledgements**

References


*Information: Sutro Biopharma, South San Francisco, CA, USA*